Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | EIF4A3 | P38919 | 6/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8159258 | 0.85 | SMN1; SMN2 (0.35) | ALOX15NFKB1BLMSMN1; SMN2KMT2A | |
| SCHEMBL12777375 | 0.85 | SMN1; SMN2 (0.35) | ALOX15NFKB1BLMSMN1; SMN2KMT2A | |
| SCHEMBL1002588 | 0.85 | XDH (0.39) | KMT2AALDH1A1 | |
| SCHEMBL1003681 | 0.82 | HCAR2 (0.42) | ALOX15NFKB1BLMSMN1; SMN2AR | |
| SCHEMBL1006240 | 0.79 | PTGS1 (0.42) | EIF4A3KMT2A | |
| SCHEMBL1004020 | 0.79 | SMN1; SMN2 (0.35) | EIF4A3ALOX15NFKB1BLMSMN1; SMN2 | |
| SCHEMBL2074449 | 0.78 | ALOX15 (0.33) | ALOX15NFKB1BLMSMN1; SMN2ALDH1A1 | |
| SCHEMBL1004549 | 0.78 | TPMT (0.34) | ALOX15NFKB1BLMSMN1; SMN2ALDH1A1 | |
| SCHEMBL1003853 | 0.77 | DDB1 (0.44) | ALDH1A1 | |
| SCHEMBL12777445 | 0.77 | DDB1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011011330-A2 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011330-A2 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20090099248-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099248-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, ACHE | TDP1 358/4885MME 906/4885EIF4A3 3143/4885 |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, ACHE | TDP1 358/4885MME 906/4885EIF4A3 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.